University:
Michigan State University
Course:
PHM 450 | Introduction to Chemical Toxicology
Academic year:

2020
Views:

456

Pages:

32
Author:

Apolenajz

Pharmacodynamics 1 Receptor Occupancy Theory The “Law” of Mass Action • Activation of membrane receptors and target cell responses is proportional to the degree of receptor occupancy. • Assumptions: – – – – – Association is limited by collision, orientation and energy All receptors are equally accessible All receptors are either free or bound, there is no “partial” binding Neither drug or receptor are altered by binding Binding is reversible ARE DRUGS THAT ANTAGONIZE CELL SURFACE RECEPTORS CLINICALLY USEFUL? Some important examples: • Angiotensin Receptor Blockers (ARBs) for high blood pressure, heart failure, chronic renal insufficiency (losartan [Cozaar®]; valsartan [Diovan®]) • Beta-Adrenoceptor Blockers for angina, myocardial infarction, heart failure, high blood pressure, performance anxiety (propranolol [Inderal®]; atenolol [Tenormin®]) Drug-receptor binding •This ratio is the equilibrium dissociation constant or KD •This dissociation constant, Kd, indicates the strength of binding between R and D in terms of how easy it is to separate the complex DR Drug Receptors & Pharmacodynamics Receptors largely determine the quantitative relations between dose (or concentration) of the drug and pharmacologic effects.   The receptor's affinity for binding a drug determines the concentration of drug required to form a significant number of drug-receptor complexes, The total number of receptors limits the maximal effect a drug can produce. KD: concentration at which binding site is 50% occupied. Affinity 1/Kd Dose response relationships • Graduate dose-response relations As the dose administrated to single subject or isolated tissue is increased , the pharmacologic effect will also increase. At a certain dose, the effect will reach a maximum level, which is called the ceiling effect or Emax. Relations between drug concentration and drug effect Potency • Potency refers to the affinity of a drug for its receptor or the concentration of drug required to produce a given effect. Low KD, high potency • • Potency refers to the amount or concentration of drug required to produce a response. • • On dose-response curves potency is measured on the X-axis. • • ED50, EC50, and Kd are measures of potency. Graduate dose-response curve efficacy • Efficacy is the maximum effect of a drug, Emax, and does depend on the number of drug-receptor complexes formed, and also on the efficiency of the of coupling of receptor activation to cellular responses. • Aspirin and morphine produce the same pharmacologic effect (analgesia) but have very different levels of efficacy. efficacy • • • If drug can stimulate a receptor to produce a biological response it is said to have efficacy or intrinsic activity. Efficacy refers to the capacity of a drug to produce an effect or the overall magnitude of the maximum response, synonymous with intrinsic activity If a drug stimulates a full response, it might to said to be a full agonist and to be very efficacious. Log dose response curve • The smaller the EC50, the greater the potency. • Efficacy is indicated by the height of the log dose response Antagonism between drugs A. Pharmacologic antagonism: occurs when an antagonist prevent an agonist from interacting with its receptors to produce an effect, and it can be either competitive or noncompetitive. Competitive antagonist compete with agonist in a reversible fashion in the receptors. The log dose-response curve is shifted to the right, indicating that a higher concentration of agonist is necessary to achieve the response. Noncompetitive antagonist binds irreversibly to the receptors site or to another side that inhibit the response to the agonist. And no matter how much agonist is given, the action of the antagonist can not overcome. The shift in the log response curve in this case is a nonparallel shift. Competitive antagonists • • • Bind agonist site Do not shift equilibrium towards active or inactive conformation “Neutral” antagonists Shift in the log-dose response Competitive antagonist Noncompetitive antagonist Agonist-Antagonist Relationships   Competitive antagonist, higher concentrations of agonist are required to produce a given effect. High agonist concentrations can overcome inhibition by a competitive antagonist. Irreversible (or noncompetitive) antagonist, reduces the maximal effect the agonist can achieve, although it may not change its EC50. Two-state model of drug-receptor interaction The receptor is postulated to exist in the inactive, nonfunctional form (Ri) and in the activated form (Ra). Thermodynamic considerations indicate that even in the absence of any agonist, some of the receptor pool must exist in the Ra form some of the time and may produce the same physiologic effect as agonistinduced activity. Agonists have a much higher affinity for the Ra configuration and stabilize it, so that a large percentage of the total pool resides in the Ra–D 20 fraction and a large effect is produced Constitutive Activity The effect of receptors, occurring in the absence of agonist, is termed constitutive activity. The recognition of constitutive activity may depend on the receptor density, the concentration of coupling molecules (if a coupled system), and the number of effectors in the system. 21 22 Inverse agonists: While antagonists are traditionally thought to have no function 23 Competitive & Irreversible Antagonists Receptor antagonists bind to receptors but do not activate the The primary action of antagonists is to reduce the effects of a Inverse agonists shift equilibrium towards the inactive conformatio Effect obvious if much constitutive activity 24 • Full agonist • Partial agonist • Antagonist   Partial inverse agonist Full inverse agonist Inverse agonists • • Inverse agonists shift equilibrium towards the inactive conformation Effect obvious if much constitutive activity Two-state model of drug-receptor interaction    Full agonists shift equilibrium “fully” towards the active conformation Partial agonists shift equilibrium “partially” towards the active conformation Sub-maximal effect with receptors completely occupied Antagonism between drugs B. Physiologic Antagonist: here the drugs act independently on two different receptors, and exemplified by one drug acting on the sympathetic nervous system causing the heart rate to increase and causing vasoconstruction; while another drug acting on the parasympathetic nervous system decrease the heart rate and causes vasodilation. C. Chemical antagonist (Antagonism by neutralization): Occurs when two drugs combine with one another to form an inactive compound, and the best example being the drugs containing sulfhydryl (SH) groups, when combine with mercury or arsenic. Enhancement of drug effects A. Additive drug effect occurs if two drugs with the same effect , when given together produce an effect that is equal in magnitude to the sum of the effect. EAB = EA + EB 1+1=2 B. Synyrgic drug effect occurs if two drugs with the same effect, when given together, produce an effect that is greater in magnitude than the sum of effects when the drugs are given individually. EAB > EA + EB 1+1>2 C. Potentiation drug effect occurs if a drug lacking an effect of its own increase the effect of a second active drug. EAB > EA + EB 0+1>2 Therapeutic index and margin of safety Therapeutic index of a drug is a ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response in a population individuals: Where TD50 is the minimum dose that is lethal or toxic for 50% of the population, and ED50 is the minimum dose that is effective for 50% of the population. Ideally the TD50 Should be a much higher dose than the ED50 so that the therapeutic index would be large. Therapeutic index and margin of safety

Pharmacodynamics

of 32

Description

Free up your schedule!

Take 5 seconds to unlock